From bodybuilding forums to mainstream conversation, peptides are no longer a fringe "biohacker" story thanks to the rise of GLP-1 popularity. They are becoming a serious capital markets story, with some even dubbing it the new frontier of medicine. The global peptide therapeutics market was estimated at $46.4 billion in 2024, and a 2026‑dated analysis estimates the market at ~USD 51.6–52.6 billion in 2025, with expectations to grow to above USD 87–139 billion by 2034–2035, powered by obesity, diabetes, oncology, and next-gen targeted therapies.

The most important update lies in its regulatory landscape, where the FDA has officially scheduled a July 23-24, 2026 advisory meeting to review whether peptide-related substances, including BPC-157, KPV, TB-500, MOTS-C, emideltide/DSIP, Semax, and Epitalon, should move toward inclusion on the 503A compounding list. The market is discussing a "12-peptide unlock" over the next 12 months. Important distinction: the FDA is reviewing compounding access, not granting full drug approvals. Even so, this signals that peptides are moving from wellness subculture into a more formal commercial lane.

The molecule drawing significant attention is Retatrutide. In a phase 2 trial published in NEJM, the triple agonist targeting GIP, GLP-1, and glucagon receptors delivered up to 24.2% mean weight loss at 48 weeks. Many investors see it as the next step beyond first-wave GLP-1 brands like Ozempic. Retatrutide, however, is not in the list. The FDA states retatrutide cannot be used in compounding under federal law and has not been found safe and effective for any condition even with mounting self-reported efficacy. The current FDA review is energising the category while the market looks toward higher-potency, multi-receptor peptide drugs.

Beyond these, the peptide landscape includes opportunities in recovery and aesthetics. BPC-157 gained attention because rat data in a transected Achilles tendon model showed accelerated healing, improved biomechanics, and reestablishment of full tendon integrity, a feat never seen with any compound before. GHK-Cu is notable in the beauty industry, worth $667 billion in 2025: published reviews cite clinical improvements in skin density, thickness, elasticity, wrinkle depth, clarity, pigmentation, and hair growth/thickness. This connects peptide science with aesthetics and function in a streamlined single compound rather than multiple products and protocols.

Put it all together and the market impact is obvious. There is bound to be more demand for peptide APIs, sterile manufacturing, compounding infrastructure, obesity platforms, recovery clinics, and med-spa/aesthetic channels. The peptide trade is no longer just “the next Ozempic". It’s starting to look like a full new layer of medicine.

Sources: Reuters, FDA, GMI, SSRP, NEJM, Pubmed, MDPI
Photos: Unsplash

Written by: Ariff Azraei Bin Mohammed Kamal